Observational Study on Patients With Hepatobiliary Tumors

NCT ID: NCT04637048

Last Updated: 2022-06-16

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-02-16
• Study Completion Date: 2023-12-01

Brief Summary

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.

Detailed Description

This is an ongoing, longitudinal, observational clinical cohort study of patients with tumors of the alimentary tract, mainly hepatobiliary tumors. All the patients are diagnosed, treated and followed up. In the future, some other patient information will be gradually updated to this database

Conditions

Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Gastric Cancer; Colorectal Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

1. Be older than 18 years old;

2. Clinical or pathological diagnosis of malignant hepatobiliary tumors;

3. Patients have received or are about to receive surgery, chemotherapy radiotherapy, targeted therapy, local therapy, immunotherapy, etc;

4. Patients understand and are willing to sign written informed consent.

Exclusion Criteria

1. Patients considered by the doctor to be unsuitable for entry into this study (mental disorder or poor compliance, etc.);

2. The patient or guardian is unwilling to participate in this study;

3. Pregnant women;

4. Combined with other serious systemic diseases (heart failure, renal failure,hematopoietic system disease or Uncontrollable acute infection);

5. Estimated survival time is less than 1 month.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gang Chen, MD

OTHER

Sponsor Role: lead

Responsible Party

Gang Chen, MD

Division Chief of Education; Deputy Director of Hepatobiliary Surgery

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Gang Chen, M.D.

Role: PRINCIPAL_INVESTIGATOR

First Affiliated Hospital of Wenzhou Medical University

Locations

Gang Chen

Wenzhou, Zhejiang, China

Countries

China

References

Yang J, Wang D, Ma L, An X, Hu Z, Zhu H, Zhang W, Chen K, Ma J, Yang Y, Wu L, Chen G, Wang Y. Sarcopenia negatively affects postoperative short-term outcomes of patients with non-cirrhosis liver cancer. BMC Cancer. 2023 Mar 6;23(1):212. doi: 10.1186/s12885-023-10643-6.

Reference Type: DERIVED

PMID: 36879265 (View on PubMed)

Other Identifiers

Obs-Hepatobiliary CA

Identifier Type: -

Identifier Source: org_study_id